Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

Detalles Bibliográficos
Autores principales: Lee, D., Amadi, A., Sabater, J., Ellis, J., Johnson, H., Kotapati, S., McNamara, S., Walker, A., Cooper, M., Patterson, K., Roskell, N., Meng, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393273/
https://www.ncbi.nlm.nih.gov/pubmed/30206825
http://dx.doi.org/10.1007/s41669-018-0096-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393273/
https://www.ncbi.nlm.nih.gov/pubmed/30206825
http://dx.doi.org/10.1007/s41669-018-0096-x

Ejemplares similares